FDA weighs black box warning for two eczema creams

Share this article:
The FDA convened an outside panel of experts this week to consider adding black box labeling to two prescription eczema creams to warn they might increase the risk of certain cancers, especially in children. The panel discussed Novartis' Elidel and Fujisawa Pharmaceuticals' Protopic after 13 reports of skin cancer and lymphoma in children and adults. Novartis said there was no evidence
Elidel causes lymphoma, noting the number of lymphomas in question "is below the number typically observed in the general population." Fujisawa said it did not believe Protopic raised the risk of skin cancer or lymphoma and that the cream "has a favorable benefit-risk ratio."
Share this article:

Email Newsletters

More in News

Lilly's cancer drug ramu granted gastric indication

Lilly's cancer drug ramu granted gastric indication

Ramucirumab received FDA approval today in advanced gastric cancer, a nod that could translate into $600 million in peak sales.

GSK, Novartis, Lilly play musical chairs

GSK, Novartis, Lilly play musical chairs

The three drugmakers rearranged part of the pharma universe Tuesday with a string of pipeline-altering deals.

Valeant bids $47B for Allergan

Valeant bids $47B for Allergan

The deal would bring Allergan's Botox and Juvederm under the same roof as Restylane.